Loading company
Alvotech
ALVO · Nasdaq · ·
Next earnings: November 11, 2026
$5.93-3.8%Sep 29 close
- 1M
- +19.7%
- 6M
- +80.1%
- 1Y
- -27.7%
- 5Y
- -39.5%
ALVO · Nasdaq · ·
Next earnings: November 11, 2026
$5.93-3.8%Sep 29 close
Alvotech is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2025 | 3 months toSep 30, 2023 | Change |
|---|---|---|---|
| Free Cash Flow | $119.8M | -$123.9M | +196.71% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Alvotech has no earnings call transcript available.
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Alvotech filed on August 19, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.